While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...

Among 84 patients evenly split in each arm, HexaBody-CD38 elicited an ORR of 55% compared to 52% in the daratumumab arm. The complete response rate was 7% for HexaBody-CD38 and 2% for daratumumab.

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a ...

Following a thorough evaluation, and rigorous portfolio prioritization, Genmab will not be pursuing further clinical development of HexaBody-CD38. Genmab said that it is "disappointed that J&J has ...

After falling behind in the early battle for delivering its anti-CD38 monoclonal antibody, isatuximab (Sarclisa), Sanofi appears poised to climb back with a hands-free injector that an ...

Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development. Quiver AI Summary Y-mAbs Therapeutics, Inc. announced the ...

U.S.-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences have launched a new company armed with $180 million in series A funds and a clinical-stage CD38-targeting ...

Genmab A/S (Nasdaq: GMAB) said on Monday that Johnson & Johnson (J&J) has decided not to exercise its option to obtain a worldwide license for the development, manufacturing, and commercialization ...